Biologics

A section of Drugs and Drug Candidates (ISSN 2813-2998).

Section Information

Biologics, or Biopharmaceuticals, can be defined as drugs derived from biological sources. Engineered proteins and glycoproteins are prominent in this field since the introduction of human insulin encoded in recombinant DNA in 1982. Biologics now include hundreds of monoclonal antibodies (some vectors for conjugated drugs), hormones, interferons and other immune regulators, bifunctional fusion proteins, blood coagulation factors and therapeutic enzymes, such as thrombolytic agents. Further, drugs based on nucleic acids and polysaccharides are being developed. Specific challenges are related to the design, production and clinical evaluation of Biologics. Potential hurdles in this research field include antigenicity and rapid in vivo clearance of Biologics. DDC invites the submission of manuscripts for its novel section Biologics.

Keywords

  • biologics
  • monoclonal antibodies
  • fusion proteins
  • interleukin
  • interferon
  • growth factor
  • therapeutic hormone
  • therapeutic enzyme
  • therapeutic fusion protein
  • drug derived from nucleic acids
  • therapeutic polysaccharides

Editorial Board

Papers Published

Back to TopTop